SUTRO BIOPHARMA, INC. Increase (Decrease) in Accounts Payable
SUTRO BIOPHARMA, INC. (STRO) reported Increase (Decrease) in Accounts Payable of -$4.23 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-12
- SUTRO BIOPHARMA, INC. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was -$1.69M.
- SUTRO BIOPHARMA, INC. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was -$2.55M.
- SUTRO BIOPHARMA, INC. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was $575.00K, a 86.05% decline year-over-year.
- SUTRO BIOPHARMA, INC. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was $2.68M.
- SUTRO BIOPHARMA, INC. increase (decrease) in accounts payable for fiscal 2025 was -$2.47M, a 449.58% decline from fiscal 2024.
- SUTRO BIOPHARMA, INC. increase (decrease) in accounts payable for fiscal 2024 was $706.00K, a 85.33% decline from fiscal 2023.
- SUTRO BIOPHARMA, INC. increase (decrease) in accounts payable for fiscal 2023 was $4.81M.
- SUTRO BIOPHARMA, INC. increase (decrease) in accounts payable for fiscal 2022 was -$1.23M, a 145.24% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month | Increase (Decrease) in Accounts Payable 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | -$1.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$4.23M 10-Q · filed 2026-08-12 | -$3.66M derived: sum of 3 quarters · filed 2026-08-12 | -$974.00K derived: sum of 4 quarters · filed 2026-08-12 | |
| 2026-03-31 | -$2.55M 10-Q · filed 2026-05-14 | -$1.97M derived: sum of 2 quarters · filed 2026-05-14 | $711.00K derived: sum of 3 quarters · filed 2026-05-14 | -$3.13M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-12-31 | $575.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $3.26M derived: sum of 2 quarters · filed 2026-03-23 | -$587.00K derived: sum of 3 quarters · filed 2026-08-12 | -$2.47M 10-K · filed 2026-03-23 | |
| 2025-09-30 | $2.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$1.16M derived: sum of 2 quarters · filed 2026-08-12 | -$3.04M 10-Q · filed 2025-11-06 | $1.08M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-06-30 | -$3.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$5.73M 10-Q · filed 2026-08-12 | -$1.60M derived: sum of 3 quarters · filed 2026-08-12 | -$1.73M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-03-31 | -$1.88M 10-Q · filed 2026-05-14 | $2.24M derived: sum of 2 quarters · filed 2026-05-14 | $2.12M derived: sum of 3 quarters · filed 2026-05-14 | $722.00K derived: sum of 4 quarters · filed 2026-05-14 | |
| 2024-12-31 | $4.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $4.00M derived: sum of 2 quarters · filed 2026-03-23 | $2.60M derived: sum of 3 quarters · filed 2026-03-23 | $706.00K 10-K · filed 2026-03-23 | |
| 2024-09-30 | -$123.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$1.52M derived: sum of 2 quarters · filed 2025-11-06 | -$3.42M 10-Q · filed 2025-11-06 | $642.00K derived: sum of 4 quarters · filed 2025-11-06 | |
| 2024-06-30 | -$1.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$3.29M 10-Q · filed 2025-08-07 | $765.00K derived: sum of 3 quarters · filed 2025-08-07 | $2.18M derived: sum of 4 quarters · filed 2025-08-07 | |
| 2024-03-31 | -$1.90M 10-Q · filed 2025-05-08 | $2.16M derived: sum of 2 quarters · filed 2025-05-08 | $3.57M derived: sum of 3 quarters · filed 2025-05-08 | $2.72M derived: sum of 4 quarters · filed 2025-05-08 | |
| 2023-12-31 | $4.06M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $5.47M derived: sum of 2 quarters · filed 2025-03-13 | $4.61M derived: sum of 3 quarters · filed 2025-03-13 | $4.81M 10-K · filed 2025-03-13 | |
| 2023-09-30 | $1.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $557.00K derived: sum of 2 quarters · filed 2024-11-13 | $755.00K 10-Q · filed 2024-11-13 | -$182.00K derived: sum of 4 quarters · filed 2025-03-13 | |
| 2023-06-30 | -$857.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$659.00K 10-Q · filed 2024-08-13 | -$1.60M derived: sum of 3 quarters · filed 2025-03-13 | -$2.72M derived: sum of 4 quarters · filed 2025-03-13 | |
| 2023-03-31 | $198.00K 10-Q · filed 2024-05-13 | -$739.00K derived: sum of 2 quarters · filed 2025-03-13 | -$1.86M derived: sum of 3 quarters · filed 2025-03-13 | $105.00K derived: sum of 4 quarters · filed 2025-03-13 | |
| 2022-12-31 | -$937.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | -$2.06M derived: sum of 2 quarters · filed 2025-03-13 | -$93.00K derived: sum of 3 quarters · filed 2025-03-13 | -$1.23M 10-K · filed 2025-03-13 | |
| 2022-09-30 | -$1.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $844.00K derived: sum of 2 quarters · filed 2023-11-13 | -$288.00K 10-Q · filed 2023-11-13 | -$2.06M derived: sum of 4 quarters · filed 2024-03-25 | |
| 2022-06-30 | $1.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $836.00K 10-Q · filed 2023-08-10 | -$940.00K derived: sum of 3 quarters · filed 2024-03-25 | $1.80M derived: sum of 4 quarters · filed 2024-03-25 | |
| 2022-03-31 | -$1.13M 10-Q · filed 2023-05-15 | -$2.91M derived: sum of 2 quarters · filed 2024-03-25 | -$166.00K derived: sum of 3 quarters · filed 2024-03-25 | $2.04M derived: sum of 4 quarters · filed 2024-03-25 | |
| 2021-12-31 | -$1.78M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $966.00K derived: sum of 2 quarters · filed 2024-03-25 | $3.17M derived: sum of 3 quarters · filed 2024-03-25 | $2.71M 10-K · filed 2024-03-25 | $6.43M 10-K · filed 2022-02-28 |
| 2021-09-30 | $2.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $4.95M derived: sum of 2 quarters · filed 2022-11-08 | $4.48M 10-Q · filed 2022-11-08 | $4.06M derived: sum of 4 quarters · filed 2023-03-30 | |
| 2021-06-30 | $2.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $1.74M 10-Q · filed 2022-08-08 | $1.32M derived: sum of 3 quarters · filed 2023-03-30 | $2.57M derived: sum of 4 quarters · filed 2023-03-30 | |
| 2021-03-31 | -$462.00K 10-Q · filed 2022-05-09 | -$887.00K derived: sum of 2 quarters · filed 2023-03-30 | $366.00K derived: sum of 3 quarters · filed 2023-03-30 | ||
| 2020-12-31 | -$425.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $828.00K derived: sum of 2 quarters · filed 2023-03-30 | -$1.14M 10-K · filed 2023-03-30 | -$947.00K 10-K · filed 2021-03-18 | |
| 2020-09-30 | $1.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$716.00K 10-Q · filed 2021-11-10 | |||
| 2020-06-30 | -$1.97M 10-Q · filed 2021-08-09 | ||||
| 2019-12-31 | $776.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $944.00K derived: sum of 2 quarters · filed 2022-02-28 | $1.78M derived: sum of 3 quarters · filed 2022-02-28 | $2.25M 10-K · filed 2022-02-28 | |
| 2019-09-30 | $168.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $1.00M derived: sum of 2 quarters · filed 2020-11-05 | $1.48M 10-Q · filed 2020-11-05 | $1.82M derived: sum of 4 quarters · filed 2021-03-18 | |
| 2019-06-30 | $833.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $1.31M 10-Q · filed 2020-08-06 | $1.65M derived: sum of 3 quarters · filed 2021-03-18 | $2.17M derived: sum of 4 quarters · filed 2021-03-18 | |
| 2019-03-31 | $476.00K 10-Q · filed 2020-05-11 | $820.00K derived: sum of 2 quarters · filed 2021-03-18 | $1.33M derived: sum of 3 quarters · filed 2021-03-18 | $874.00K derived: sum of 4 quarters · filed 2021-03-18 | |
| 2018-12-31 | $344.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | $859.00K derived: sum of 2 quarters · filed 2021-03-18 | $398.00K derived: sum of 3 quarters · filed 2021-03-18 | $209.00K 10-K · filed 2021-03-18 | |
| 2018-09-30 | $515.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $54.00K derived: sum of 2 quarters · filed 2019-11-08 | -$135.00K 10-Q · filed 2019-11-08 | -$786.00K derived: sum of 4 quarters · filed 2020-03-16 | |
| 2018-06-30 | -$461.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | -$650.00K 10-Q · filed 2019-08-14 | -$1.30M derived: sum of 3 quarters · filed 2020-03-16 | ||
| 2018-03-31 | -$189.00K 10-Q · filed 2019-05-15 | -$840.00K derived: sum of 2 quarters · filed 2020-03-16 | |||
| 2017-12-31 | -$651.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | -$473.00K 10-K · filed 2020-03-16 | |||
| 2017-09-30 | $178.00K 10-Q · filed 2018-11-14 | ||||
| 2016-12-31 | $874.00K 10-K · filed 2019-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 |